MX2016012712A - Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad. - Google Patents

Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.

Info

Publication number
MX2016012712A
MX2016012712A MX2016012712A MX2016012712A MX2016012712A MX 2016012712 A MX2016012712 A MX 2016012712A MX 2016012712 A MX2016012712 A MX 2016012712A MX 2016012712 A MX2016012712 A MX 2016012712A MX 2016012712 A MX2016012712 A MX 2016012712A
Authority
MX
Mexico
Prior art keywords
inhalable
related conditions
treating age
rapamycin formulation
rapamycin
Prior art date
Application number
MX2016012712A
Other languages
English (en)
Inventor
M Rothberg Jonathan
Lichenstein Henri
ARMER Thomas
S Melvin Lawrence
Original Assignee
Lam Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lam Therapeutics Inc filed Critical Lam Therapeutics Inc
Publication of MX2016012712A publication Critical patent/MX2016012712A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a métodos y composiciones para terapia anti-envejecimiento y para el tratamiento y profilaxis de enfermedades y trastornos relacionados con la edad en un sujeto humano en necesidad de tal terapia o tratamiento, los métodos que comprenden la administración al sujeto, de manera preferente a través de inhalación, de la composición que comprende rapamicina, o un profármaco derivado de la misma.
MX2016012712A 2014-04-04 2015-04-06 Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad. MX2016012712A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461975127P 2014-04-04 2014-04-04
PCT/US2015/024551 WO2015154084A1 (en) 2014-04-04 2015-04-06 An inhalable rapamycin formulation for treating age-related conditions

Publications (1)

Publication Number Publication Date
MX2016012712A true MX2016012712A (es) 2017-03-31

Family

ID=53005668

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016012712A MX2016012712A (es) 2014-04-04 2015-04-06 Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
MX2022004103A MX2022004103A (es) 2014-04-04 2016-09-28 Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022004103A MX2022004103A (es) 2014-04-04 2016-09-28 Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.

Country Status (21)

Country Link
US (4) US20170014341A1 (es)
EP (2) EP3125875B1 (es)
JP (2) JP6525285B2 (es)
KR (1) KR102352249B1 (es)
CN (1) CN106659686A (es)
AU (1) AU2015240485B2 (es)
BR (1) BR112016022598A8 (es)
CA (1) CA2944075C (es)
DK (1) DK3125875T3 (es)
ES (1) ES2952025T3 (es)
FI (1) FI3125875T3 (es)
HR (1) HRP20230863T1 (es)
HU (1) HUE062742T2 (es)
IL (1) IL248048A0 (es)
MX (2) MX2016012712A (es)
NZ (1) NZ724756A (es)
PL (1) PL3125875T3 (es)
PT (1) PT3125875T (es)
RS (1) RS64482B1 (es)
RU (1) RU2718583C2 (es)
WO (1) WO2015154084A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
CA2899206C (en) 2013-01-24 2019-07-09 Transderm, Inc. Compositions for transdermal delivery of mtor inhibitors
EP3054948B1 (en) 2013-10-08 2020-08-12 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
EP3125875B1 (en) 2014-04-04 2023-06-07 AI Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
AU2015330905B2 (en) 2014-10-07 2021-02-25 AI Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MA40910A (fr) * 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
PT109030B (pt) * 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
PT109117B (pt) 2016-01-28 2019-02-01 Hovione Farm Sa Complexação de ingredientes ativos farmacêuticos
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
CN108926533B (zh) * 2017-05-24 2022-03-25 江苏天士力帝益药业有限公司 一种替西罗莫司脂质体及其制备方法
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
MD3962455T2 (ro) * 2020-05-18 2022-12-31 Orexo Ab Compoziție farmaceutică nouă pentru livrare de medicamente
CN113444730A (zh) * 2021-03-17 2021-09-28 昆明市延安医院 一种原发性肝细胞klotho基因转导干细胞筛选构建方法
EP4236921A1 (en) 2021-11-25 2023-09-06 Orexo AB Pharmaceutical composition comprising adrenaline
CN114796208B (zh) * 2022-05-27 2024-01-23 上海海洋大学 雷帕霉素在制备预防或治疗鲫造血器官坏死病药物中的应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2517482A (en) 1949-04-09 1950-08-01 Sharp & Dohme Inc Inhaler
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
DE3345722A1 (de) 1983-12-17 1985-06-27 Boehringer Ingelheim KG, 6507 Ingelheim Inhalator
GB8909891D0 (en) 1989-04-28 1989-06-14 Riker Laboratories Inc Device
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
AU688782B2 (en) 1993-09-30 1998-03-19 Wyeth Rapamycin formulations for oral administration
PL319600A1 (en) 1994-09-29 1997-08-18 Andaris Ltd Spray-dried microparticles as therapeutic carriers
US5635161A (en) 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
DE19523516C1 (de) 1995-06-30 1996-10-31 Asta Medica Ag Inhalator zum Verabreichen von Medikamenten aus Blisterpackungen
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
AU735648B2 (en) 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
JP2001513078A (ja) 1996-12-30 2001-08-28 バテル・メモリアル・インスティテュート 吸入により新生物を治療する製剤とその方法
US6451784B1 (en) 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US20040039047A1 (en) 1998-08-11 2004-02-26 Mark Zamoyski Compositions and methods for treating lung cancers
DE60001623T2 (de) 1999-12-03 2003-12-18 Pfizer Prod Inc Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
US20040018228A1 (en) 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
WO2003015521A1 (en) 2001-08-20 2003-02-27 Transave, Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
EP1424889A4 (en) 2001-08-20 2008-04-02 Transave Inc PROCESS FOR TREATING LUNG CANCERS
WO2003099362A1 (en) 2002-05-20 2003-12-04 Research Development Foundation Aerosol drug inhibition of lung metastases
US20050070567A1 (en) 2002-08-12 2005-03-31 The Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
KR101369631B1 (ko) 2002-08-21 2014-03-05 노턴 헬스케어 리미티드 흡입용 조성물
ES2685436T3 (es) * 2002-12-09 2018-10-09 Abraxis Bioscience, Llc Composiciones y procedimientos para administración de agentes farmacológicos
UA83484C2 (uk) 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
US20050119330A1 (en) 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
AR043504A1 (es) * 2003-03-17 2005-08-03 Novartis Ag Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
AR050374A1 (es) 2004-08-20 2006-10-18 Wyeth Corp Forma polimorfica de rafampicina
JP2008514706A (ja) 2004-09-29 2008-05-08 コーディス・コーポレイション 安定非晶質ラパマイシン様化合物の薬学的投与形態
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
FR2882366B1 (fr) 2005-02-18 2008-04-18 Coletica Sa Polymere reticule de carbohydrate, notamment a base de polysaccharides et/ou de polyols
JP2008531686A (ja) 2005-03-02 2008-08-14 ワイス ラパマイシンの精製
US20080275076A1 (en) 2005-03-08 2008-11-06 Per Holm Pharmaceutical Compositions Comprising Sirolimus and/or an Analogue Thereof
BRPI0606282A2 (pt) 2005-03-17 2009-06-09 Elan Pharma Int Ltd composições injetáveis de compostos imunossupressores em nanopartìculas
CN1883474A (zh) 2005-06-22 2006-12-27 华北制药集团新药研究开发有限责任公司 一种含大环内酯类化合物和多孔水不溶性亲水性载体的组合物
US7446096B2 (en) 2005-12-19 2008-11-04 Industrial Technology Research Institute Glutathione based delivery system
CN101340901A (zh) 2005-12-20 2009-01-07 惠氏公司 通过控制药物物质杂质控制cci-779剂型稳定性
GB0602123D0 (en) 2006-02-02 2006-03-15 Novartis Ag Organic compounds
CN104000818B (zh) 2006-02-02 2017-11-21 诺瓦提斯公司 结节性硬化症治疗
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
RU2009122202A (ru) * 2006-11-10 2010-12-20 Биокон Лимитед (In) Чистая форма рапамицина и способ ее выделения и очистки
US8414909B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
WO2008063576A2 (en) 2006-11-20 2008-05-29 Lutonix, Inc. Drug releasing coatings for medical devices
EP1938800A1 (en) 2006-12-06 2008-07-02 Ranbaxy Laboratories Limited Sirolimus nanodispersion
EP1952807A1 (en) 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Sirolimus formulation
RU2478387C2 (ru) 2007-02-20 2013-04-10 Новартис Аг ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR
CA2686736A1 (en) 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension
EP2252275B1 (en) 2008-02-13 2017-11-29 Board of Regents, The University of Texas System Templated open flocs of anisotropic particles for enhanced pulmonary delivery
DK2365802T3 (da) 2008-11-11 2017-11-13 Univ Texas Mikrokapsler af rapamycin og anvendelse til behandling af cancer
KR20110104120A (ko) 2009-01-26 2011-09-21 테바 파마슈티컬 인더스트리즈 리미티드 극미립자를 이용한 담체 코팅 방법
US20100196483A1 (en) * 2009-02-04 2010-08-05 Activaero Gmbh Research & Development Method for treatmentof severe and uncontrollable asthma
GB0905818D0 (en) 2009-04-06 2009-05-20 Airbus Uk Ltd Coupling assembly
ES2685947T3 (es) 2009-04-10 2018-10-15 Haiyan Qi Agentes antienvejecimiento
GB0908129D0 (en) 2009-05-12 2009-06-24 Innovata Ltd Composition
US9248110B2 (en) 2010-03-18 2016-02-02 Steven Lehrer Compositions and methods of treating and preventing lung cancer and lymphangioleiomyomatosis
PT105058B (pt) 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
US20110318277A1 (en) 2010-06-25 2011-12-29 APT Pharmaceuticals, Inc. University of Maryland, Baltimore Tacrolimus compositions for aerosol administration
US20140037548A1 (en) 2010-06-28 2014-02-06 The Board Of Trustees Of The Leland Standford Junior University Treatment and prevention of diffuse parenchymal lung disease by selective active-site mTOR inhibitors
CA2812952A1 (en) 2010-09-27 2012-04-12 Microdose Therapeutx, Inc. Methods and compositions for disease treatment using inhalation
CN102670518B (zh) 2011-03-14 2014-08-20 齐鲁制药有限公司 一种难溶性药物球形颗粒的制备方法
US20140067548A1 (en) 2012-08-31 2014-03-06 Sap Ag Saving on device functionality for business calendar
EP2979123A4 (en) 2013-03-28 2017-05-03 EndoChoice, Inc. Compact multi-viewing element endoscope system
EP3054948B1 (en) * 2013-10-08 2020-08-12 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
RU2016136348A (ru) 2014-02-11 2018-03-16 Лэм Терапьютикс, Инк. Рапамицин для лечения лимфангиолейомиоматоза
EP3125875B1 (en) * 2014-04-04 2023-06-07 AI Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
DE102014005466A1 (de) 2014-04-12 2015-10-15 Klaus Düring Verfahren zur Gewinnung von Napin und Cruciferin oder einem Gemisch davon aus Raps
AU2015330905B2 (en) 2014-10-07 2021-02-25 AI Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016130645A1 (en) * 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
CN108039392A (zh) 2017-11-06 2018-05-15 北京汉能薄膜发电技术有限公司 铜铟镓硒化合物、油墨及其薄膜吸收层制备方法

Also Published As

Publication number Publication date
PT3125875T (pt) 2023-06-29
FI3125875T3 (fi) 2023-08-24
KR20160141776A (ko) 2016-12-09
JP2017509684A (ja) 2017-04-06
EP4218742A1 (en) 2023-08-02
US11103449B2 (en) 2021-08-31
EP3125875A1 (en) 2017-02-08
DK3125875T3 (da) 2023-07-24
HUE062742T2 (hu) 2023-12-28
WO2015154084A1 (en) 2015-10-08
RU2718583C2 (ru) 2020-04-08
AU2015240485A1 (en) 2016-10-20
BR112016022598A2 (pt) 2017-08-15
MX2022004103A (es) 2022-04-26
IL248048A0 (en) 2016-11-30
US20230240986A1 (en) 2023-08-03
CN106659686A (zh) 2017-05-10
RS64482B1 (sr) 2023-09-29
JP6525285B2 (ja) 2019-06-05
PL3125875T3 (pl) 2023-11-20
BR112016022598A8 (pt) 2021-06-29
CA2944075C (en) 2022-06-28
ES2952025T3 (es) 2023-10-26
RU2016143365A (ru) 2018-05-08
AU2015240485B2 (en) 2020-05-14
US20210212942A1 (en) 2021-07-15
JP2019142934A (ja) 2019-08-29
RU2016143365A3 (es) 2018-11-14
US11648199B2 (en) 2023-05-16
CA2944075A1 (en) 2015-10-08
EP3125875B1 (en) 2023-06-07
US20190133938A1 (en) 2019-05-09
NZ724756A (en) 2023-07-28
KR102352249B1 (ko) 2022-01-17
HRP20230863T1 (hr) 2023-11-10
US20170014341A1 (en) 2017-01-19

Similar Documents

Publication Publication Date Title
MX2022004103A (es) Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
MX2016010373A (es) Rapamicina para el tratamiento de linfangioleiomiomatosis.
PH12016501750A1 (en) Human plasma kallikrein inhibitors
TW201613901A (en) New compounds
MX2017004440A (es) Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar.
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MX2016004530A (es) Rapamicina para el tratamiento de linfangioleiomiomatosis.
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2015012435A (es) Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmicos.
MX2015010829A (es) Compuestos terapeuticos y sus usos.
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2018000262A (es) Usos terapeuticos de formulaciones de berberina.
MX2017004760A (es) Formulacion esterilizada por calor que comprende quitosan y proceso para preparacion de la misma.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MY195767A (en) Treatment of Androgen Deprivation Therapy Associated Symptoms
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
IL252543B (en) Compounds for the treatment of degenerative retinal tissues
MX2017003016A (es) Derivados de piridazinona como inhibidores de las fosfoinositido-3-cinasas.
MX2018003564A (es) 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer.
MX2015012393A (es) Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina.